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Abstract
While the primary motor cortex (M1) is know to receive dopaminergic projections, the functional role of
these projections is poorly characterized. Here, it is hypothesized that dopaminergic signals modulate
M1 excitability and somatotopy, two features of the M1 network relevant for movement execution and
learning. To test this hypothesis, movement responses evoked by electrical stimulation using an
electrode grid implanted epidurally over the caudal motor cortex (M1) were assessed before and after an
intracortical injection of D1-
(R-(+),8-chloro,7-hydroxy,2,3,4,5,-tetra-hydro,3-methyl,5-phenyl,1-H,3-benzazepine maleate, SCH
23390) or D2-receptor (raclopride) antagonists into the M1 forelimb area of rats. Stimulation mapping
of M1 was repeated after 24 h. D2-inhibition reduced the size of the forelimb representation by 68.5%
(P<0.001). Movements thresholds, i.e., minimal currents required to induce movement responses
increased by 37.5% (P<0.001), and latencies increased by 35.9% (P<0.01). Twenty-4 h after the
injections these effects were reversed. No changes were observed with D1-antagonist or vehicle. By
enhancing intracortical excitability and signal transduction, D2-mediated dopaminergic signaling may
affect movement execution, e.g. by enabling task-related muscle activation synergies, and learning.
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Abbreviations 
DA: dopamine 
GABA: γ-aminobutyric acid 
IPSP: evoked inhibitory postsynaptic potential 
M1: primary motor cortex 
NMDA: N-methyl-D-aspartate 
PD: Parkinson’s disease  
PFC: prefrontal cortex 
SCH 23390: R-(+),8-chloro,7-hydroxy,2,3,4,5,-tetra-hydro,3-methyl,5-phenyl,1-H,3-       
benzazepine maleat 
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Abstract 
While it has been shown that the primary motor cortex (M1) receives dopaminergic 
projections, the functional role of these projections is poorly characterized. Here, it is 
hypothesized that dopaminergic signals modulate M1 excitability and somatotopy, two 
features of the M1 network relevant for movement execution and learning.  
To test this hypothesis, movement responses evoked by electrical stimulation using an 
electrode grid implanted epidurally over the caudal motor cortex (M1) were assessed before 
and after an intracortical injection of D1- (SCH 23390) or D2- receptor (raclopride) 
antagonists into the M1 forelimb area of rats. Stimulation was repeated after 24 hours. 
D2-inhibition reduced the size of the forelimb representation by 68.5% (p<0.001). 
Movements thresholds, i.e., minimal currents required to induce movement responses 
increased by 37.5% (p<0.001), and latencies increased by 35.9% (p<0.01). Twenty-four hours 
after the injections these effects were reversed. No changes were observed with D1-antagonist 
or vehicle.  
By enhancing the intracortical excitability and signal transduction, D2-mediated 
dopaminergic signalling may affect movement execution, e.g., by enabling task-related 
muscle activation synergies, and learning. 
Key words: dopamine, somatotopy, motor cortex, stimulation mapping, multielectrode array 
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Introduction 
The neocortex receives dopaminergic projections via the mesocortical pathway from 
the ventral tegmental and adjacent areas containing dopaminergic neurons (Seamans and 
Yang, 2004; Smythies, 2005).  Rostral regions of cortex receive denser dopaminergic 
projections than caudal regions, but for both, primates (Williams and Goldman-Rakic, 1993) 
and rodents (Berger et al., 1991), dopaminergic projections to primary motor cortex (M1) 
were demonstrated. 
Dopamine (DA) acts through two biochemically and pharmacologically characterized 
families of receptors (Civelli et al., 1993). D1 receptors (D1a, D5) stimulate adenylate cyclase 
thereby increasing intracellular cyclic 3’-5’-AMP (cAMP) levels (Kebabian and Calne, 1979). 
In contrast, D2 receptors (D2, D3, D4) inhibit adenylate cyclase (Onali et al., 1984).  Both 
types of receptors are present in the rodent and primate neocortex and show inhomogeneous 
distribution across cortical layers. D1 receptors are present in superficial (layer I, II, IIIa) and 
deep (V and VI) layers (for rodents: Savasta et al., 1986; for primates: (Lidow et al., 1991)). 
D2 receptors are expressed primarily in layer V but tenfold less than D1 (for rodents: Ariano 
et al., 1993; for primates: Lidow et al., 1991). Additionally, different types of cortical neurons 
show different DA receptor expression profiles (Williams and Goldman-Rakic, 1993; Bergson 
et al., 1995, Gorelova et al., 2002). In rat prefrontal cortex and M1, co-localization of both 
subtypes were observed in layer V/VI pyramidal cells (Awenowicz and Porter, 2002). 
Although it seems plausible that dopaminergic input modulates motor function, its 
physiological role is still poorly defined. Depletion of M1 dopaminergic terminals by 
intracortical injection of 6-hydroxydopamine did not impair performance of a skilled reaching 
task (Whishaw et al., 1992). It may be that motor cortical DA has a specific role in 
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movement learning (Pekanovic et al., 2007; Rioult-Pedotti et al., 2007). On the cellular level, 
partially contradictory information exists on the effects of DA on network activity (reviewed 
by Seamans and Yang, 2004; Smythies, 2005). Information on how DA affects motor cortical 
network activity is necessary to understand its role for behaviour. 
The objective here is to investigate how DA affects motor cortical excitability and 
somatotopy. Both are features of M1 that play important roles for motor function and learning 
(Pascual-Leone et al., 1995; Nudo et al., 1996; Monfils et al., 2005; Molina-Luna et al., 
2008). 
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Experimental procedures 
Animals and experiments 
Seventeen male Long-Evans rats (8-10 weeks, 250-350g) were included in this study. 
Animals were housed individually in a 12/12-hr light/dark cycle. After electrode implantation, 
animals were allowed to recover for five days. Stimulation mapping was performed at 
baseline (session 1 “base”), 30min after intracortical microinjection of DA antagonists 
(session 2 ”injection”), and after 24 hours (mapping session 3 “recovery”). Each session 
lasted 1.5 – 2 hours. Between sessions 2 and 3, animals were returned to their home cages.   
Surgical procedures 
A thin-film polyimide-based microelectrode array was implanted epidurally together with 
a cannula for intracortical drug application. The electrode array, surgical procedures and the 
stimulation technique were described previously (Molina-Luna et al., 2007 and 2008). In 
brief, a craniotomy over the right hemisphere was performed (coordinates for the motor 
cortex with respect to Bregma; 4 mm posterior, 5 mm anterior, 5 mm lateral, 2 mm medial) 
under ketamine/xylazine (70/10mg/kg i.p.) anaesthesia. The electrode array was placed over 
the caudal motor cortex. The guide cannula (15mm long, Unimed SA, Lausanne, Switzerland) 
was slowly inserted through a preformed hole in the polyimid-matrix of the array to a depth of 
900 µm and protected with an obturator. Positioning of the array in the middle of the 
craniotomy ensured that the hole came to lie close to the centre of the forelimb representation 
in the right M1 (2 mm anterior and 2 mm lateral with respect to bregma). The cannula hub 
and the array’s connector plugs were anchored onto the rats’ skull with screws and bone 
cement. 
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 The microelectrode array consisted of a 14µm thin polyimide foil, 6mm x 7mm in size 
(42mm2), with 72 titanium nitrite contacts (diameter 100µm) in a grid arrangement with 
intercontact distances of 640 µm in medio-lateral and 750 in anterior-posterior direction. For 
cortical microstimulation, 61 contacts were used, 8 contacts were short-circuited to form the 
reference electrode, and three contacts were not connected for technical reasons (wiring 
layout of the connector plug, # 1, 33 and 64). Thus, a mapping resolution of roughly 1 
contact/0.69 mm2 was obtained. The impedances of the contacts ranged between 5 and 10 k• 
at 1 kHz. A flat polyimide cable connected the electrode to a connector piece. Perforations of 
100µm diameter in the polyimide structure between the contacts allowed for fluid diffusion. 
The array is commercially available (Mulltichannel Systems, www.multichannelsystems.com, 
Reutlingen, Germany). 
Epidural stimulation and drug application 
For stimulation mapping, animals were sedated with 40-50 mg/kg i.p. ketamine. 
Stimulation was started when whisker tremors of small amplitude, typical for ketamine 
anaesthesia of superficial to medium depth were observed (Kisley and Gerstein, 1999). The 
stimulation procedure was performed as previously described (Molina-Luna et al., 2007 and 
2008). Briefly, biphasic stimuli consisting of constant current pulses (100 stimuli in 300 Hz, 
constant current of +/- 1–4.8mA, per electrode) were routed serially to contacts in random 
order. During mapping, the animal was suspended in a sleeve with the limbs hanging freely to 
allow for recording (via acceleration sensors attached to each limb) and observation (video 
footage) of evoked limb movements. Using these video recordings, the primary joint (distal 
forelimb including wrist and elbow, proximal forelimb including shoulder and neck and 
hindlimb including foot and knee) involved in evoked movement was determined. For 
confirmation, the magnitude of the acceleration sensor signal was utilized as a metric to 
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compare different limbs (Molina-Luna et al., 2008). For each contact, an evoked movement 
was only considered if it was verified, i.e., after a movement response was obtained, the 
stimulation current was decreased until the response disappeared and then increased again 
until the response reappeared or a maximum of 4.8 mA was reached. In the latter case, the 
response was not verified and the contact was considered non-responsive. The stimulus 
intensity required to verify a movement response was considered as the motor threshold. 
Response latency was the time between the stimulus and the first deflection of the 
accelerometer signal. 
To test the effect of D1- and D2 receptor antagonization, rats received intracortical 
injections of the D1 antagonist SCH 23390 (n=6, 600µg/µl, Tocris Biosciences, Avonmouth, 
UK, compare Dalley et al., 2005), the D2 antagonist raclopride (n=6, 10µg/µl, S(–)-
Raclopride (+)-tartrate salt, compare Chausmer and Ettenberg, 1999) or vehicle solution (n=5, 
saline 0.9%) 30 min before starting mapping session 2. A needle (34 Gauge, same length as 
guide cannula) was lowered into the guide cannula. A volume of 0.5µl was injected over 
90sec using a microsyringe (5µl, Hamilton Bonaduz AG, Switzerland) connected to the 
needle via polyethylene tubing (10cm, PE40 Plastics One, Roanoke, VA USA), and a 
microinjection pump (Nano-injector, Stoelting Co., Wood Dale, IL, USA). 
Data Analysis 
Analyses were performed using Statistica version 7.0 (StatSoft Inc., Tulsa, OK, USA) and 
MatLab (Version 7, The MathWorks Inc., Natick, MA, USA). The size of a representation 
was quantified by the number of responsive contacts per limb or joint. The representation area 
in mm² can be obtained by multiplying the number of contacts with 0.48. If a contact was 
dysfunctional due to manufacturing defects or damage during implantation (mean of 
1.27±0.07 positions per experiment, constant across mapping sessions), the missing value was 
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estimated by the average of the neighbouring contacts. Motor maps were visualized using 
SigmaPlot (Version 10.9, SPSS Inc., Chicago, Illinois, USA). Repeated measures analysis of 
variance was performed with group (SCH23390, raclopride or saline) and joint (distal 
forelimb, proximal forelimb and hindlimb) as between subjects factors, time (three time 
points) as within-subjects factor and the interaction of group x time x joint. Baseline map size 
was entered as a continuous covariate in the model to avoid false positive results caused by 
baseline differences. The sphericity assumption was tested using the Mauchly criterion. If this 
test was significant, Greenhouse-Geisser correction was used. Post hoc tests were performed 
using Bonferroni correction for multiple comparisons. Neck and whisker movement were not 
included in the analyses because they were infrequently and less accurately detected (absence 
of acceleration sensors). Paired student’s t-tests were used to compare spatial distances 
towards the injection site. Numerical results are expressed as mean and SEM.  
Histological assessment of brain injury 
The brains were evaluated for signs of tissue damage and for verification of guide cannula 
placement. Coronal sections (50µm) were Nissl-stained and inspected using a microscope 
(x10 and x40 magnification) (Figure 1). 
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Results 
Effects of DA antagonists on representation size 
At baseline, the number of responsive contacts as a measure of representation size was 
not different between groups (p=0.45). 
The size of the distal forelimb representation shrunk after injection of the D2 
antagonist raclopride (n=6) but not after the administration of the D1-receptor antagonist SCH 
23390 (n=6) or vehicle (n=5) and recovered 24h later (Figure 2 and 3). In the model 
predicting representation size, the interaction between group x time x joint was significant 
(F(8,70)=6.3 p<0.001). Therefore, separate models were computed for each joint. For distal 
forelimb but not for proximal forelimb or hindlimb, we found a significant group x time 
interaction (F=(4,70)=9.4, p<0.001). For the distal forelimb, post-hoc analysis revealed a 
decrease of responsive contacts after raclopride injection (map 1: 16.8±3.1 contacts – map 2: 
5.3±0.7 contacts; p<0.001), which was reversible after one day of recovery (map 3: 16.0±3.1 
contacts; p<0.001).  
Effects of DA antagonists on stimulation thresholds 
At baseline, stimulation threshold as a measure of cortical excitability did not differ 
between groups (p=0.35). 
Motor thresholds for all joints increased after the injection of raclopride and recovered after 
24h. D1-receptor antagonist or vehicle injections had no effect (Figure 4A). In the model 
predicting stimulation thresholds, the interaction between group x time was significant 
(F(4,54)=2.9, p=0.029). The interaction between group x time x joint (p=0.8) as well as the 
main effect of joint (p=0.96) were insignificant and the variable joint was 
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dropped from the model. For the raclopride group, post-hoc analysis showed a significant 
increase in stimulation thresholds after injection (map 1: 1.6±0.1mA – map 2: 2.2±0.2mA; 
p<0.001), which was reversible after 24h of recovery (map 3: 1.7±0.3 mA p<0.001, Figure 
4A).  
Effects of DA-antagonists on movement latencies 
 At baseline the shortest latencies were observed for proximal forelimb (57.96±6.79 
ms), followed by distal forelimb (wrist/elbow; 85.29±6.01 ms) and hindlimb (171.77±12.65 
ms; effect of joint on latency: F(2, 24)=32.92, p<0.001). The group factor did not influence 
the latency at baseline (p=0.67). 
D2-antagonist injections prolonged the latency. The effect was reversed at 24 hours. 
D1-antagonist or vehicle had no effect (Figure 4B and C). In the model predicting latency, 
the group x time interaction was significant (F(4,46)=5.62, p<0.001). The interaction between 
group x time x joint (p=0.28) as well as the main effect of joint (p=0.4) were insignificant and 
the variable joint was dropped from the model. Post hoc analysis revealed a significant 
increase in latencies after raclopride injection (map 1: 108.7±13.4 ms – map 2: 147.3±20.9 
ms; p=0.008) and a consecutive decrease after 24h (map 3: 99.7±14.1 ms p=0.006).  
Cannula placement 
The center of the wrist/elbow representation was closer to the injection site (1.9 ± 0.09 
mm) than the hindlimb (2.24±1.6 mm; paired t-test: p=0.021) and the shoulder/neck 
representation (2.11±2.0 mm; paired t-test: p=0.05). Intracortical placement of the guide 
cannula was verified histologically for all 17 animals. Except for the cannula tract, no further 
signs of cortical injury or scar formation were observed (Figure 1). 
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Discussion 
Only intracortical injections of D2- but not the D1 antagonist transiently reduced cortical 
excitability thereby reducing the size of the forelimb representation and increasing motor 
threshold. The decrease in representation size is the consequence of reduced excitability 
because the representation is no longer accessible from distant contacts where applying 
maximum stimulation current does surpass the elevated motor threshold. In addition, latencies 
are increased reflecting the activation of a smaller pool of neurons or slowed signal 
transduction through cortical networks (assuming that epidural microstimulation activates 
primary motor neurons transsynaptically, Molina-Luna et al. 2007). 
D2 receptor specificity 
In contrast to D2, the D1 antagonist did not affect cortical excitability or evoked response 
latencies. This is surprising, because D1 receptors are more abundant in M1 (Lidow et al., 
1991) and often have counteracting effects due to their opposite action on adenylate cyclase 
(Seeman and Van Tol, 1994). But as argued by Seamens and Yang (2004), the effects of 
dopaminergic modulation critically depend on (1) the cortical layer where modulation takes 
place, (2) concentrations of DA or antagonists and (3) the experimental timeline. 
Regarding 1, the vertical intracortical spread of the drug covers all cortical layers as 
shown previously using India ink injection using the identical injection technique (Luft et al., 
2004). Hence, a bias due to a inhomogeneous distribution across cortical layers is unlikely.  
Regarding 2, while at low concentrations DA predominantly acts via D1 receptors, D2 
receptor activation requires higher DA concentrations (Trantham-Davidson et al., 2004). 
When present in such high concentrations, DA does act as a partial D1 receptor antagonist 
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(Seamans and Yang, 2004). So far, no measurements of DA concentrations in M1 have been 
performed. However, repetitive high-frequency stimulation (here: 300 Hz; 100 pulses) at 
increasing stimulation intensities may reach – at least in the synaptic cleft – high phasic DA 
levels that might effectively activate D2 receptors and partially block D1 receptors 
simultaneously  (Seamans and Yang, 2004). This physiological action of DA may have been 
obstructed by the D2 antagonist. 
Regarding 3, DA can have early or delayed effects on cortical neurons. Hence, the effect 
will depend on the time point at which measurements are taken. For layer V pyramidal cells in 
prefrontal cortex, Seamans and colleagues (2001) showed a biphasic dopaminergic 
modulation of neuronal activity: a fast-onset presynaptic D2-mediated depression of 
inhibitory post-synaptic currents (IPSC) was followed by a delayed, long-lasting and D1-
mediated IPSC increase. A similar biphasic effect on excitatory postsynaptic potentials has 
been described for hippocampal CA1 pyramidal cells (fast-onset D2 mediated decrease 
followed by a delayed D1 induced increase, Gribkoff and Ashe, 1984; Huang and Kandel, 
1995). In our experimental time line we may have captured early D2-mediated effects only. 
The fact that the D1-antagonist had no effect, could have been influenced by Ketamine 
anaesthesia. Ketamine is an N-methyl-D-aspartate (NMDA)-antagonist and reciprocal 
interactions between D1-receptors and NMDA-receptors have been reported. Activation of 
NMDA-receptors recruits D1-receptors from the interior of the cell to the plasma membrane 
(Scott et al., 2002). Additionally, activation of D1-receptors increased NMDA-evoked 
currents in pyramidal neurons in PFC (Chen et al., 2004). Hence, D1-receptor mediated 
enhancement of glutamatergic signalling might enhance excitability in cortical circuits. 
Blocking NMDA-receptors with Ketamine could occlude this effect. However, using no 
anesthesia would produce unacceptable discomfort. Other anesthetics, e.g. barbiturates and 
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gases like isoflurane, depress corticomotor evoked potentials even at low concentrations 
(Calancie et al., 1991; Chiba et al., 1998). Propofol may be an alternative (Luft et al, 2001) 
but GABA-agonist effects and the need for repeated venous canulations reduce its value as 
compared with Ketamine. Ketamin plus Xylazine is known to produce little effects on CMEP 
amplitudes (Zandieh et al., 2003).  
 Forelimb specific effects of D2 antagonist 
The effects of D2 inhibition on representation size were found for wrist/elbow 
representations, which were closest to the injection site, but not for shoulder or hindlimb, 
likely reflecting the limited spread of the drug around the injection site consistent with 
previous findings (Luft et al., 2004). In contrast, no joint specificity was found for stimulation 
threshold and latencies. This may be related to the fact that representation size is measured on 
a discrete scale while threshold and latency are continuous measures. If the concentration of 
the drug drops beyond a threshold, sudden cessation of its effect on a discrete measure is 
expected, while continuous parameters are gradually affected. 
Modulation of M1 excitability by D2-receptors 
 In humans systemic application of DA-antagonists increases M1 excitability (Ziemann 
et al., 1997). Similarly, Parkinson’s disease (PD) patients in whom dopaminergic neurons 
degenerate, have increased M1 excitability (for review, Boroojerdi, 2002). These results seem 
contrary to our findings. The discrepancy is most likely explained by the fact that DA-
antagonist were applied systemically affecting all dopaminergic system in the brain; these 
systems are also all affected by PD. Interfering with basal ganglia dopaminergic 
neurotransmission also affects cortex: Antagonization of striatal DA receptors stimulates 
excitatory thalamo-cortical projections thereby increasing cortical excitability (DeLong, 1990; 
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Berardelli et al., 1996; Ziemann et al., 1997). 
D2 receptor activation potentially alters M1 excitability through different mechanisms: 
(1) direct reduction of the excitability of primary motor neurons, (2) a depression of excitatory 
(glutamatergic) synaptic transmission, or (3) an increase in inhibitory (GABAergic) synaptic 
transmission. 
 Regarding 1, DA applied into M1 in wake cats lead to increased excitability during a 
conditioned placing response (Storozhuk et al., 1998 and 2004). Similarly, in layer V of 
primate motor cortex, DA increased spontaneous activity in approximately 40% of the DA 
responsive neurons (Sawaguchi et al., 1986). These findings are consistent with our 
observations. In contrast, Awenowicz and Porter (2002) described a reduction in excitability 
of motoneurons mediated through an activation of somatically located D1- and D2- receptors 
in rats (Awenowicz and Porter, 2002). These conflicting results may be attributable to 
different experimental settings. In the latter study, iontophertical application of DA and its 
agonists/antagonistits in the immediate vicinity of the cell body was performed. Thus, given 
that DA receptors show an inhomogeneous subcellular distribution (Bergson et al., 1995), a 
different subset of receptors may be activated/blocked than in our experiments where the 
drugs were delivered to the entire cell. Alternatively, as discussed above, application of 
exogenous DA at unphysiological doses may critically influence results, because the receptor 
subtype preference (D1 vs. D2) depends on DA concentrations (Trantham-Davidson et al., 
2004).  
Regarding 2, in the monkey prefrontal and motor cortex (Goldman-Rakic et al., 1989) 
as well as the human temporal cortex (Smiley et al., 1992), dopaminergic terminals have been 
shown to target dendritic spines and shafts in close proximity to excitatory synapses 
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suggesting that DA modulates excitatory inputs. D2 receptors have been shown to reduce 
AMPA receptor mediated currents via presynaptic (CA1, rat; Otmakhova et al., 1999) and 
postsynaptic mechanisms (rat striatum and human cerebral cortex; Cepeda et al., 1992 and 
1993). D2 receptor dependent depression of NMDA receptor mediated currents has been 
observed in rat striatum, VTA and CA1 (Huang and Kandel, 1995; Hsu et al.,1995 ; Levine et 
al., 1996; Otmakhova et al., 1999; Koga and Momiyama, 2000). In rat motor cortex, DA 
depresses activity of pyramidal tract neurons evoked by stimulation of transcallosal and 
thalamocortical afferents via D1 and D2 receptors (Huda et al., 1999 and 2001). Hence, DA 
likely depresses excitatory synapses. D2 antagonization should have the opposite effect, 
hence, should enhance M1 excitability. Because this is contrary to our findings, the D2-
mediated modulation of excitatory synapses cannot be assumed as an underlying mechanism 
here.   
 Regarding 3, in the frontal cortex of rodents and primates, dopaminergic terminals 
form synapses on dendrites of GABAergic cells (Sesack et al., 1995; Le Moine and Gaspar, 
1998). These neurons are fast-spiking interneurons containing the calcium binding protein 
parvalbumin (‘basket-cells’, Sesack et al., 1998; Porter et al., 2000; Gorelova et al., 2002). 
These interneurons exert a strong perisomatic inhibition thereby effectively controlling 
primary motor neuron excitability (Markram et al., 2004). In the basal ganglia, D2 receptor 
activation decreases GABA release (Harsing and Zigmond, 1997) by a presynaptic 
mechanism (Cooper and Stanford, 2001; Momiyama and Koga, 2001). In prefrontal cortex, 
results are heterogeneous (Sesack and Bunney, 1989; Seamans and Yang, 2004). IPSPs 
measured in layer V PFC pyramidal neurons are depressed by D2 activation. This is mediated 
by a presynaptic reduction of transmitter release in fast-spiking interneurons as well as a 
direct postsynaptic modulation of GABAA receptors (Seamans et al., 2001; Gorrelova et al., 
 17
2002; Seamans and Yang, 2004). If a similar mechanism exists in M1, blocking D2 receptors 
with raclopride should increase the inhibitory drive on M1 output neurons and reduce M1 
excitability – in line with our findings. For PFC, Seamans and colleagues (2001) introduced a 
computational model to simulate the effects of D1 and D2 receptor activation on network 
activity. They describe a “D2-receptor-dominated” state defined by a net reduction in 
inhibition that allows for a preservation of activity that is thereby kept in the working memory 
buffer. Our findings suggest that this model may also be applicable to M1. 
D2-receptor mediated increase in movement latencies 
 Manipulation of the balance between inhibition and excitation not only influences 
excitability and somatotopy (Jacobs and Donoghue, 1991) but may also affect movement 
latencies through desynchronization of intracortical signalling. Increased movement latencies 
have been described after blocking metabotropic glutamate receptors during a conditioned 
reaction in cats (Storozhuk et al., 2004). This effect was reversed by DA application. Hence, 
D2 antagonization may interfere with these mechanisms thereby increasing latencies.  
Functional implications for awake and behaving animals  
 Modulating M1 excitability, somatotopy and motor conduction time has an influence 
on motor function and movement learning (Pascual-Leone et al., 1995; Nudo et al., 1996; 
Monfils et al., 2005; Molina-Luna et al., 2008; Rioult-Pedotti et al., 2007; Pekanovic et al., 
2007). Training-induced enlargement of representations is necessary for successful motor 
learning (Conner et al., 2003). In humans, motor learning is accompanied by an increase in 
M1-excitability (Pascual-Leone et al., 1995). It therefore seems likely that D2-mediated 
effects on M1 have their physiological role in movement execution and/or learning.  
In the dopaminergic projection between the ventral tegmental area (VTA) and the 
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prefrontal cortex (PFC), DA is released in bursts as a response to appetitive or novel stimuli 
(Romo and Schultz, 1990) or as background tonic activity (Seamans and Yang, 2004). This 
study cannot discern the effects of phasic versus tonic release on M1-excitability. However, 
the dopaminergic tone in PFC is negligible under anaesthetesia (Seamans and Yang, 2004). If 
the same is true for M1, we have more likely affected phasic DA-release – possibly triggered 
by the electrical stimulation – than the tonic release. 
Conclusion 
Dopaminergic neurotransmission in M1 modulates cortical excitability and somatotopy. 
This effect is mediated by D2 receptors and may be caused by dopaminergic modulation of 
GABAergic signalling. Through these effects, DA may serve to harmonize motor action 
patterns and possibly task-related muscle synergies to enable precise movements. In addition, 
it may play a role in movement learning.                       
 
 
 19
Acknowledgements 
This work was supported by a grant from the IZKF of the University of Tübingen 
(E0500139.2) and the Deutsche Forschungsgemeinschaft (Sonderforschungsbereich 550, C12, 
Lu 748/5). We are very thankful to Rüdiger Berndt for his continuous support.  
 20
References 
Ariano MA, Fisher RS, Smyk-Randall E, Sibley DR, Levine MS (D2 dopamine 
receptor distribution in the rodent CNS using anti-peptide antisera. Brain Res 609:71-
80.1993). 
Awenowicz PW, Porter LL (Local application of dopamine inhibits pyramidal tract 
neuron activity in the rodent motor cortex. J Neurophysiol 88:3439-3451.2002). 
Berardelli A, Rona S, Inghilleri M, Manfredi M (Cortical inhibition in Parkinson's 
disease. A study with paired magnetic stimulation. Brain 119 ( Pt 1):71-77.1996). 
Berger B, Verney C, Alvarez C, Vigny A, Helle KB (New dopaminergic terminal fields 
in the motor, visual (Area 18b) and retrosplenial cortex in the young and adult rat. 
Imunnocytochemical and catecholamine histochemical analyses. Neuroscience 15:983-
998.1991). 
Bergson C, Mrzljak L, Smiley JF, Pappy M, Levenson R, Goldman-Rakic PS 
(Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine 
receptors in primate brain. J Neurosci 15:7821-7836.1995). 
Boroojerdi B (Pharmacologic influences on TMS effects. J Clin Neurophysiol 19:255-
271.2002). 
Calancie B, Klose KJ, Baier S, Green BA (Isoflurane-induced attenuation of motor 
evoked potentials caused by electrical motor cortex stimulation during surgery.  J Neurosurg 
74(6):897-904. 1991). 
 21
 
Cepeda C, Radisavljevic Z, Peacock W, Levine MS, Buchwald NA (Differential 
modulation by dopamine of responses evoked by excitatory amino acids in human cortex. 
Synapse 11:330-341.1992). 
Cepeda C, Buchwald NA, Levine MS (Neuromodulatory actions of dopamine in the 
neostriatum are dependent upon the excitatory amino acid receptor subtypes activated. Proc 
Natl Acad Sci U S A 90:9576-9580.1993). 
Chausmer A, Ettenberg A (Intraaccumbens raclopride attenuates amphetamine-induced 
locomotion, but fails to prevent the response-reinstating properties of food reinforcement. 
Pharm Biochem Behav 62(2):299-305. 1999) 
Chen G, Greengard P, Yan Z (Potentiation of NMDA receptor currents by dopamine D1 
receptors in prefrontal cortex. PNAS 101(8):2596-2600. 2003). 
Chiba A, Nakanishi H, Hiruma S, Satou T, Hashimoto S, Chichibu S (Magnetically 
induced motor evoked potentials and H-reflex during nembutal and ketamine anesthesia 
administration in rats. Res Commun Mol Pathol Pharmacol 101(1):43-57.1998). 
Civelli O, Bunzow JR, Grandy DK (Molecular diversity of the dopamine receptors. 
Annu Rev Pharmacol Toxicol 33:281-307.1993). 
Cooper AJ, Stanford IM (Dopamine D2 receptor mediated presynaptic inhibition of 
striatopallidal GABA(A) IPSCs in vitro. Neuropharmacology 41:62-71.2001). 
Conner JM, Culberson A, Packowski C, Chiba AA, Tuszynski MH (Lesions of the 
Basal forebrain cholinergic system impair task acquisition and abolish cortical plasticity 
 22
associated with motor skill learning. Neuron 38:819-829.2003). 
Dalley JW, Lääne K, Theobald DEH, Armstrong HC, Corlett PR, Chudasama Y, 
Robbins TW (Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA 
receptors in the nucleus accumbens. PNAS 102(17):6189-6194. 2005) 
DeLong MR (primate models of movement disorders of basal ganglia origin. Trends 
Neurosci 13(7):281-285.1990) 
Goldman-Rakic PS, Leranth C, Williams SM, Mons N, Geffard M (Dopamine synaptic 
complex with pyramidal neurons in primate cerebral cortex. Proc Natl Acad Sci U S A 86: 
9015-9019.1989). 
Gorelova N, Seamans JK, Yang CR (Mechanisms of dopamine activation of fast-
spiking interneurons that exert inhibition in rat prefrontal cortex. J Neurophysiol 88:3150-
3166.2002). 
Gribkoff VK, Ashe JH (Modulation by dopamine of population responses and cell 
membrane properties of hippocampal CA1 neurons in vitro. Brain Res 292:327-338.1984). 
Gulledge AT, Jaffe DB (Dopamine decreases the excitability of layer V pyramidal cells 
in the rat prefrontal cortex. J Neurosci 18:9139-9151.1998). 
Gulledge AT, Jaffe DB (Multiple effects of dopamine on layer V pyramidal cell 
excitability in rat prefrontal cortex. J Neurophysiol 86:586-595.2001). 
Harsing LG, Jr., Zigmond MJ (Influence of dopamine on GABA release in striatum: 
evidence for D1-D2 interactions and non-synaptic influences. Neuroscience 77:419-
429.1997). 
 23
Huang YY, Kandel ER (D1/D5 receptor agonists induce a protein synthesis-dependent 
late potentiation in the CA1 region of thr hippocampus- Proc Natl Acad Sci USA 92:2446-
2450.1995).  
Huda K, Salunga TL, Chowdhury SA, Kawashima T, Matsunami K (Dopaminergic 
modulation of transcallosal activity of cat motor cortical neurons. Neurosci Res 33:33-
40.1999). 
Huda K, Salunga TL, Matsunami K (Dopaminergic inhibition of excitatory inputs onto 
pyramidal tract neurons in cat motor cortex. Neurosci Lett 307:175-178.2001). 
Hsu KS, Huang CC, Yang CH, Gean PW (Presynaptic D2 dopaminergic receptors 
mediate inhibition of excitatory synaptic transmission in rat neostriatum. Brain Res 690:264-
268.1995). 
Jacobs KM, Donoghue JP (Reshaping the cortical motor map by unmasking latent 
intracortical connections. Science 251:944-947.1991). 
Kebabian JW, Calne DB (Multiple receptors for dopamine. Nature 277:93-96.1979). 
Kisley MA, Gerstein GL (Trial-to-trial variability and state-dependent modulation of 
auditory-evoked responses in cortex. J Neurosci 19:10451-10460.1999). 
Koga E, Momiyama T (Presynaptic dopamine D2-like receptors inhibit excitatory 
transmission onto rat ventral tegmental dopaminergic neurones. J Physiol 523 Pt 1:163-
173.2000). 
Le Moine C, Gaspar P (Subpopulations of cortical GABAergic interneuron’s differ by 
their expression of D1 and D2 dopamine receptor subtype. Brain Res Mol Brain Res 58(1-
 24
2):231-236.1998) 
Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P (Distribution of dopaminergic 
receptors in the primate cerebral cortex: quantitative autoradiographic analysis using 
[3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 40:657-671.1991). 
Luft AR, Kaelin-Lang A, Hauser TK, Cohen LG, Thakor NV, Hanley DF 
(Transcranial magnetic stimulation in the rat. Exp Brain Res 140(1):112-21. 2001)  
Luft AR, Buitrago MM, Ringer T, Dichgans J, Schulz JB (Motor skill learning depends 
on protein synthesis in motor cortex after training. J Neurosci 24(29):6515-6520.2004). 
Markram H, Toledo-Rodriguez M, Wang Y, Gupta A, Silberberg G, Wu C 
(Interneurons of the neocortical inhibitory system. Nat Rev Neurosci 5:793-807.2004). 
Momiyama T, Koga E (Dopamine D(2)-like receptors selectively block N-type Ca(2+) 
channels to reduce GABA release onto rat striatal cholinergic interneurones. J Physiol 
533:479-492.2001). 
Molina-Luna K, Hertler B, Buitrago MM, Luft AR (Motor learning transiently changes 
cortical somatotopy. Neuroimage 40:1748-1754.2008). 
Molina-Luna K, Buitrago MM, Hertler B, Schubring M, Haiss F, Nisch W, Schulz JB, 
Luft AR (Cortical stimulation mapping using epidurally implanted thin-film microelectrode 
arrays. J Neurosci Methods 161:118-125.2007). 
Monfils MH, Plautz EJ, Kleim JA (In search of the motor engram: motor map plasticity 
as a mechanism for encoding motor experience. Neuroscientist 11:471-483.2005). 
Nudo RJ, Milliken GW, Jenkins WM, Merzenich MM (Use-dependent alterations of 
 25
movement representations in primary motor cortex of adult squirrel monkeys. J Neurosci 
16:785-807.1996). 
Onali P, Olianas MC, Gessa GL (Selective blockade of dopamine D-1 receptors by SCH 
23390 discloses striatal dopamine D-2 receptors mediating the inhibition of adenylate cyclase 
in rats. Eur J Pharmacol 99:127-128.1984). 
Otmakhova NA, Lisman JE (Dopamine selectively inhibits the direct cortical pathway 
to the CA1 hippocampal region. J Neurosci 19:1437-1445.1999). 
Pascual-Leone A, Nguyet D, Cohen LG, Brasil-Neto JP, Cammarota A, Hallett M 
(Modulation of muscle responses evoked by transcranial magnetic stimulation during the 
acquisition of new fine motor skills. J Neurophysiol 74:1037-1045.1995). 
Pekanovic A, Molina-Luna K, Hertler B, Schubring-Giese M, Röhrich S, Luft AR 
(Motor learning and dopaminergic signaling in motor cortex I: effects of DA inhibition. 
Poster presented at the Annual meeting of the society for Neuroscience, San Diego, CA. 
2007) 
Porter LL, Matin D, Keller A (Characteristics of GABAergic neurons and their synaptic 
relationships with intrinsic axons in the cat motor cortex. Somatosens Mot Res 17:67-
80.2000). 
Rioult-Pedotti MS, Molina-Luna K, Hosp J, Hertler B, Luft AR (Synaptic plasticity and 
excitability depends on dopaminergic signaling in motor cortex. Poster presented at the 
Annual meeting of the society for Neuroscience, San Diego, CA. 2007)  
Romo R, Schultz W (Dopamine neurons of the monkey midbrain: contingencies of 
responses to active touch during self-initiated arm movements. J Neurophysiol 63(3):592-
 26
606.1990). 
Sawaguchi T, Matsumura M, Kubota K (Catecholamine sensitivities of motor cortical 
neurons of the monkey. Neurosci Lett 66:135-140.1986). 
Sawaguchi T, Matsumura M, Kubota K (Dopamine enhances the neuronal activity of 
spatial short-term memory task in the primate prefrontal cortex. Neurosci Res 5:465-
473.1988). 
Savasta M, Dubois A, Scatton B (Autoradiographic localization of D1 dopamine 
receptors in the rat brain with [3H]SCH 23390. Brain Res 375:291-301.1986). S 
Scott L, Kruse M, Forssberg H, Brismar H, Greengard P, Aperia A (Selective up-
regulation of dopamine D1 receptors in dendritic spines by NMDA receptor activation. PNAS 
99(3):1661-1664. 2001). 
Seamans JK, Gorelova N, Durstewitz D, Yang CR (Bidirectional dopamine modulation 
of GABAergic inhibition in prefrontal cortical pyramidal neurons. J Neurosci 21:3628-
3638.2001). 
Seamans JK, Yang CR (The principal features and mechanisms of dopamine 
modulation in the prefrontal cortex. Prog Neurobiol 74:1-58.2004). 
Seeman P, Van Tol HH (Dopamine receptor pharmacology. Trends Pharmacol Sci 
15(7):264-270.1994). 
Sesack SR, Bunney BS (Pharmacological characterization of the receptor mediating 
electrophysiological responses to dopamine in the rat medial prefrontal cortex: a 
microiontophoretic study. J Pharmacol Exp Ther 248:1323-1333.1989). 
 27
Sesack SR, Snyder CL, Lewis DA (Axon terminals immunolabeled for dopamine or 
tyrosine hydroxylase synapse on GABA-immunoreactive dendrites in rat and monkey cortex. 
J Comp Neurol 363:264-280.1995). 
Sesack SR, Hawrylak VA, Melchitzky DS, Lewis DA (Dopamine innervation of a 
subclass of local circuit neurons in monkey prefrontal cortex: ultrastructural analysis of 
tyrosine hydroxylase and parvalbumin immunoreactive structures. Cereb Cortex 8:614-
622.1998). 
Smiley JF, Williams SM, Szigeti K, Goldman-Rakic PS (Light and electron 
microscopic characterization of dopamine-immunoreactive axons in human cerebral cortex. J 
Comp Neurol 321:325-335.1992). 
Smythies J (Section II. The dopamine system. Int Rev Neurobiol 64:123-172.2005). 
Storozhuk VM, Sanzharovsky AV, Busel BI (Interaction between dopamine and 
glutamate in the sensorimotor cortex during conditioned placing reaction. Neuroscience 
85:347-359.1998). 
Storozhuk VM, Khorevin VI, Rozumna NM, Villa AE, Tetko IV (Dopamine 
modulation of glutamate metabotropic receptors in conditioned reaction of sensory motor 
cortex neurons of the cat. Neurosci Lett 356:127-130.2004). 
Trantham-Davidson H, Neely LC, Lavin A, Seamans JK (Mechanisms underlying 
differential D1 versus D2 dopamine receptor regulation of inhibition in prefrontal cortex. J 
Neurosci 24:10652-10659.2004). 
Williams SM, Goldman-Rakic PS (Characterization of the dopaminergic innervation of 
 28
the primate frontal cortex using a dopamine-specific antibody. Cereb Cortex 3:199-222.1993). 
Whishaw IQ, Castaneda E, Gorny BP (Dopamine and skilled limb use in the rat: more 
severe bilateral impairments follow substantia nigra than sensorimotor cortex 6-
hydroxydopamine injection. Behav Brain Res 47:89-92.1992). 
Zandieh S, Hopf R, Redl H, Schlag MG (The effect of ketamine/xylazine anesthesia on 
sensory and motor evoked potentials in the rat. Spinal Cord 41(1):16-22. 2003). 
Ziemann U, Tergau F, Bruns D, Baudewig J, Paulus W (Changes in human motor 
cortex excitability induced by dopaminergic and anti-dopaminergic drugs. Electroencephalogr 
Clin Neurophysiol 105:430-437.1997). 
 
 
 
 29
Figure Legends 
Figure 1. Histological verification of cannula placement in one exemplary animal shows 
the cannula tract located in the primary mortorcortex (M1) forelimb area (M1 borders derived 
from Paxinos and Watson, 1998). No signs of cortical injury or scar formation are detectable 
(Nissl stain, arrow indicates cannula tract). 
Figure 2. Effect of DA antagonists on somatotopy. Injection of the D2 antagonist raclopride 
(0,5µl, 10µg/µl; n=6) reduces the size of the distal forelimb (wrist and elbow) representation. 
The effect is reversed after one day of recovery. No changes were detected for D1 antagonist 
SCH 23390 (0.5µl, 600ng/µl; n=6) and vehicle injections (0.5µl, 0.9% saline; n=5). 
Representation size is measured by the number of contacts evoking a given joint movement 
(size in mm² can be determined by multiplication with 0.48). Arrows indicate the day of drug 
injection. Error bars represent SEM, */** indicates post-hoc p<0.05/0.01. 
Figure 3. Exemplary motor cortex maps of the distal forelimb representations 
(wrist/elbow) derived from exemplary animals representing each group. Injection of 
raclopride induces a reversible breakdown of representation size. In contrast, application of 
SCH 23390 and saline exerts no effect. The color code reflects the motor threshold at a given 
position (in mA). The red arrowhead indicates the position of the bregma, white dots indicate 
the location of the injection cannulas, white crosses indicate the position of electrode contacts 
aligned in our electrode array. R: rostral; C: caudal; M: medial; L: lateral 
Figure 4. Effect of DA antagonists on stimulation threshold and movement latencies. (A)  
application of the D2 antagonist raclopride (0.5µl, 10µg/µl; n=6) reversibly increases 
stimulation thresholds of all joints. D1 antagonist SCH 23390 (0.5µl, 600ng/µl; n=6) and 
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vehicle (0.5µl, 0.9% saline; n=5) had no effects. (B) Raclopride injection significantly 
prolongs movement latencies for all joints. Again, the effect recovered after 24h and was not 
seen after D1 antagonist or vehicle injection. (C) Exemplary acceleration sensor traces 
obtained from elbow movements. Movements were evoked by stimulation of a constant 
contact during the three successive mapping sessions and demonstrate the raclopride-induced 
increase in movement latencies. Arrows indicate the day of drug injection. Error bars 
represent SEM, ** indicates post-hoc p<0.01 
(Gulledge and Jaffe, 1998) 
(Sawaguchi et al., 1988) 
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